Europe Biosimilar Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The Europe biosimilar market was valued at USD 11.43 Billion in 2025. It is poised to grow at a CAGR of 12.80% during the forecast period of 2026-2035, and reach USD 38.12 Billion by 2035. The market growth benefits from supportive regulatory frameworks led by the European Medicines Agency and cost-containment initiatives accelerating biosimilar adoption. The increasing biologic patent expirations and growing physician confidence in biosimilar safety and efficacy will expand utilization during the forecast period. The rising investments in biosimilar research, manufacturing expansion, and favorable reimbursement incentives will enhance accessibility and sustain robust regional growth.

Key Market Trends and Insights

• By molecule, the insulin glargine segment is projected to lead the market in the forecast period.
• Based on the indication, the autoimmune diseases segment held approximately 39% of the market share in the historical period.
• By manufacturing type, the in-house manufacturing segment is likely to hold a significant share of the forecast period.

Market Size and Forecast

• Market Size (2025): USD 11.43 Billion
• Projected Market Size (2035): USD 38.12 Billion
• CAGR (2026-2035): 12.80%

Europe Biosimilar Market Overview

Biosimilars are increasingly shaping pharmaceutical competition by expanding therapeutic access and reducing treatment costs across oncology, immunology, and chronic disease management. Strong regulatory pathways, patent expirations of biologics, and payer pressure are accelerating adoption while encouraging innovation in manufacturing efficiency and stakeholder confidence. The market demonstrates robust maturity, supported by harmonized regulatory frameworks, physician acceptance, and proactive reimbursement policies across major economies. The market was valued at USD 11.43 Billion in 2025, driven by expanding indications, hospital procurement initiatives, and competitive pricing strategies that enhance overall healthcare sustainability.

Europe Biosimilar Market Growth Drivers

Expanding Biosimilar Launches to Enhance the Market Value and Accessibility in Europe

The increasing introduction of cost-effective biosimilars for high-burden chronic conditions is a major driver accelerating the market. In November 2025, Sandoz announced the European launch of Afqlir® (aflibercept), following its European Commission approval in November 2024, offering an affordable alternative for retinal diseases such as neovascular age-related macular degeneration. The product demonstrated comparable efficacy, safety, and pharmacokinetics to the reference biologic while expanding access across key European markets, including the United Kingdom, Germany, and France. Such strategic launches strengthen biosimilar adoption, reduce healthcare costs, and significantly support sustained market growth across Europe.

Europe Biosimilar Market Trends

Some of the notable trends in the market include rising strategic patent settlements and accelerated biosimilar commercialization, along with increasing regulatory approvals for complex biosimilars.

Rising Strategic Patent Settlements and Accelerated Biosimilar Commercialization to Propel the Market Expansion

The market is witnessing a growing trend of strategic patent settlements and regulatory clearances that accelerate commercialization timelines for complex biologics. These agreements are enabling manufacturers to secure defined market entry dates while minimizing litigation risks and improving patient access to cost-effective therapies. For instance, in December 2025, Biocon Biologics Limited announced a settlement with Amgen Inc. to commercialize its denosumab biosimilars across Europe following earlier European Commission approval in July 2025. Such developments are expected to strengthen competition, expand therapeutic availability, and support sustained market growth across the region.

Growing Regulatory Approvals for Complex Biosimilars are Likely to Enhance Europe Biosimilar Market Landscape

The expansion of regulatory approvals for complex biologics in oncology and bone-related disorders, driven by increasing demand for cost-effective therapeutic alternatives, is a key market trend. For instance, in July 2025, Fresenius Kabi received European Commission approval for its denosumab biosimilars Conexxence® and Bomyntra®, covering multiple indications such as osteoporosis and cancer-related bone complications. Such approvals demonstrate growing confidence in biosimilar efficacy and safety while encouraging portfolio diversification among manufacturers. This trend is expected to accelerate product adoption and significantly contribute to sustained market growth across Europe.

Europe Biosimilar Market Segmentation

Market Breakup by Molecule

• Insulin Glargine
• Etanercept
• Somatropin
• Follitropin Alfa
• Infliximab
• Epoetin Alfa
• Filgrastim
• Rituximab
• Adalimumab
• Others

Market Breakup by Indication

• Blood Disorder
• Oncology
• Female Infertility
• Autoimmune Diseases
• Growth Deficiency
• Diabetes
• Others

Market Breakup by Manufacturing Type

• In-House Manufacturing
• Contract Manufacturing

Market Breakup by Country

• United Kingdom
• Germany
• France
• Italy
• Spain

Europe Biosimilar Market Share

Autoimmune Diseases Segment is Poised to Lead the Market Based on the Indication

The market is segmented by indication into blood disorders, oncology, female infertility, autoimmune diseases, growth deficiency, diabetes, and others. Among these, the autoimmune diseases segment is expected to witness significant growth due to the rising burden of chronic immune-mediated conditions and strong adoption of cost-effective biologic alternatives. The increasing psoriasis incidence is a key growth driver; for instance, a 2025 study by Charbel SKAYEM et al. reported a prevalence of 4.6% in the region. The expanding treatment access and favorable reimbursement policies further reinforce segment leadership, supporting sustained market expansion.

Europe Biosimilar Market Analysis by Region

The regions included in the report are the United Kingdom, Germany, France, Italy, and Spain. Among these, the United Kingdom is expected to lead the market due to the strong regulatory support, centralized procurement, and rapid adoption of cost-effective biologics. For instance, in December 2025, Alvotech and Advanz Pharma announced the European launch of a golimumab biosimilar, supported by a tender award from NHS England. This structured reimbursement framework accelerates biosimilar uptake, enhances patient access to advanced therapies, and reinforces the country’s leadership in regional market growth.

Leading Players in the Europe Biosimilar Market

The key features of the market report comprise clinical trials and pipeline analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Sandoz AG

Sandoz AG is a global leader in biosimilars and generics, with a longstanding commitment to expanding access to biologic therapies. The company pioneered biosimilar development in 1996 and has since built a broad portfolio targeting chronic and complex conditions such as autoimmune diseases, diabetes, and oncology. Its biosimilars provide cost-effective alternatives to reference biologics, supporting healthcare system sustainability and patient access. Through continuous innovation, regulatory expertise, and large-scale manufacturing capabilities, the company remains a key participant in the biosimilar market.

Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader with a strong presence in biologics and biosimilars, focusing on complex therapies derived from natural systems to treat oncology, immunology, and chronic diseases. The company develops biosimilars designed to match the safety and efficacy of licensed reference biologics through rigorous comparative studies. Its expanding biosimilar portfolio supports broader patient access to advanced treatments while addressing healthcare cost challenges. Pfizer’s ongoing research, manufacturing expertise, and pipeline development reinforce its strategic involvement in the biosimilar market and its commitment to improving treatment accessibility worldwide.

Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical manufacturer with a strong presence in the biosimilar market, supported by more than a century of industry expertise. The company offers a portfolio of nine approved biosimilars and maintains a pipeline exceeding 20 candidates, reflecting its commitment to expanding affordable biologic treatment options. Through its integrated development and manufacturing capabilities, Teva focuses on improving patient access to high-quality therapies while strengthening its competitive position in the evolving biosimilars landscape worldwide.

Celltrion Healthcare

Celltrion Healthcare is a leading global company focused on the commercialization and distribution of biosimilars across autoimmune diseases and oncology. The company has demonstrated strong market involvement through its oncology monoclonal antibody biosimilars, including rituximab, which gained significant adoption following launches in Europe in 2017 and 2018. These products have been widely prescribed across European healthcare systems, reflecting positive clinical acceptance and cost-effectiveness. Celltrion Healthcare’s expanding biosimilar portfolio and early market entry strategy continues to strengthen its position in the biosimilar market.

Other key players in the market are Samsung Bioepis, Amgen Inc., Mylan N .V., Merck Sharp & Dohme Corp., Accord Healthcare Ltd., and Boehringer Ingelheim.

Key Questions Answered in the Europe Biosimilar Market

• What was the Europe biosimilar market value in 2025?
• What is the Europe biosimilar market forecast outlook for 2026-2035?
• What major factors aid the demand for the Europe biosimilar market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Europe biosimilar market trends?
• Which molecule is expected to dominate the market segment?
• Which indication is projected to lead the market segment?
• Which manufacturing type is anticipated to drive the market segment?
• Who are the key players in the Europe biosimilar market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?